Gilead Sciences Inc.
Gilead Sciences Reports Second Quarter 2025 Financial Results and Raises Guidance
Summary
Gilead Sciences, Inc. reported its second quarter 2025 financial results, showing total revenue of $7.1 billion, up 2% year-over-year. Product sales excluding Veklury increased by 4% to $6.9 billion, driven by higher sales of HIV medications, including Biktarvy and Descovy. Gilead also raised its revenue and earnings guidance for the full year 2025. The company announced a new $6.0 billion stock repurchase program and a quarterly dividend of $0.79 per share. Gilead also shared updates on its product pipeline, including the FDA approval for Yeztugo for HIV prevention and positive trial results for Trodelvy in metastatic triple-negative breast cancer.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement